Aurinia Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Thank you for joining. My name is Michael Klem. I'm a member of JPMorgan's Healthcare Investment Banking team. It's my pleasure to introduce Peter Greenleaf, the CEO of Aurinia Pharmaceuticals. He's joined here with Joe Miller, the CFO; Neil Solomons, the CMO; and Glenn Schulman, SVP of IR. (Operator Instructions)
Without further ado, I'll turn it over to you, Peter.
Thanks, Michael, and I want to thank everybody at JPMorgan for having us here at the conference today, and for all investors who sort of lasted through the entire day of activity to join us as we're back and clean up. But we're excited to be here today. Before I get started, obviously, I would just point you towards our website for all most recent filings with the SEC.
As part of our forward-looking statements to start my presentation. While I'm going to just speak freely about who we are, where the business is and where we're going, there is a slide deck, corporate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |